Development of histone deacetylase inhibitors for cancer treatment

References

• Santos-Rosa H, Caldas C. Chromatin modifier enzymes, the histone code and cancer. Eur. J. Cancer41(16), 2381–2402 (2005).
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat. Med.10(8), 789–799 (2004).
   PubMed Web of Science ®Google Scholar
• Allfrey VG, Faulkner R, Mirsky AE. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc. Natl Acad. Sci. USA51, 786–794 (1964).
   PubMed Web of Science ®Google Scholar
• Grunstein M. Histone acetylation in chromatin structure and transcription. Nature389(6649), 349–352 (1997).
   PubMed Web of Science ®Google Scholar
• Bird A. DNA methylation patterns and epigenetic memory. Genes Dev.16(1), 6–21 (2002).
   PubMed Web of Science ®Google Scholar
• Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med.349(21), 2042–2054 (2003).
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet.3(6), 415–428 (2002).
   PubMed Web of Science ®Google Scholar
• Jones DO, Cowell IG, Singh PB. Mammalian chromodomain proteins: their role in genome organisation and expression. Bioessays22(2), 124–137 (2000).
   PubMed Web of Science ®Google Scholar
• Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov.1(4), 287–299 (2002).
   PubMed Web of Science ®Google Scholar
• Taddei A, Roche D, Bickmore WA, Almouzni G. The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy? EMBO Rep.6(6), 520–524 (2005).
   PubMed Web of Science ®Google Scholar
• Yang WM, Tsai SC, Wen YD, Fejer G, Seto E. Functional domains of histone deacetylase-3. J. Biol. Chem.277(11), 9447–9454 (2002).
   PubMed Web of Science ®Google Scholar
• Yang WM, Yao YL, Sun JM, Davie JR, Seto E. Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. J. Biol. Chem.272(44), 28001–28007 (1997).
   PubMed Web of Science ®Google Scholar
• Gao L, Cueto MA, Asselbergs F, Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem.277(28), 25748–25755 (2002).
   PubMed Web of Science ®Google Scholar
• Longo VD, Kennedy BK. Sirtuins in aging and age-related disease. Cell126(2), 257–268 (2006).
   PubMed Web of Science ®Google Scholar
• Denu JM. The Sir 2 family of protein deacetylases. Curr. Opin. Chem. Biol.9(5), 431–440 (2005).
   PubMed Web of Science ®Google Scholar
• Buck SW, Gallo CM, Smith JS. Diversity in the Sir2 family of protein deacetylases. J. Leukoc. Biol.75(6), 939–950 (2004).
   PubMed Web of Science ®Google Scholar
• Vigushin DM, Coombes RC. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs13(1), 1–13 (2002).
   PubMed Web of Science ®Google Scholar
• Marks P, Rifkind RA, Richon VM et al. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer1(3), 194–202 (2001).
   PubMed Web of Science ®Google Scholar
• Jung M. Inhibitors of histone deacetylase as new anticancer agents. Curr. Med. Chem.8(12), 1505–1511 (2001).
   PubMed Web of Science ®Google Scholar
• Kelly WK, O’Connor OA, Marks PA. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin. Investig. Drugs11(12), 1695–1713 (2002).
   PubMed Web of Science ®Google Scholar
• Arts J, de Schepper S, Van Emelen K. Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. Curr. Med. Chem.10(22), 2343–2350 (2003).
   PubMed Web of Science ®Google Scholar
• Sengupta N, Seto E. Regulation of histone deacetylase activities. J. Cell. Biochem.93(1), 57–67 (2004).
   Google Scholar
• Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J. Cell Biochem.96(2), 293–304 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yamashita H, Toyama T et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res. Treat.94(1), 11–16 (2005).
   PubMed Web of Science ®Google Scholar
• Krusche CA, Wulfing P, Kersting C et al. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res. Treat.90(1), 15–23 (2005).
   PubMed Web of Science ®Google Scholar
• Choi JH, Kwon HJ, Yoon BI et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn. J. Cancer Res.92(12), 1300–1304 (2001).
   PubMedGoogle Scholar
• Toh Y, Yamamoto M, Endo K et al. Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma. Oncol. Rep.10(2), 333–338 (2003).
   PubMed Web of Science ®Google Scholar
• Saji S, Kawakami M, Hayashi S et al. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene24(28), 4531–4539 (2005).
   PubMed Web of Science ®Google Scholar
• Varshochi R, Halim F, Sunters A et al. ICI182,780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor α from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line. J. Biol. Chem.280(5), 3185–3196 (2005).
   PubMed Web of Science ®Google Scholar
• Osada H, Tatematsu Y, Saito H et al. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int. J. Cancer112(1), 26–32 (2004).
   PubMed Web of Science ®Google Scholar
• Zhu P, Martin E, Mengwasser J et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell5(5), 455–463 (2004).
   PubMed Web of Science ®Google Scholar
• Bradbury CA, Khanim FL, Hayden R et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia19(10), 1751–1759 (2005).
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov.5(9), 769–784 (2006).
   PubMed Web of Science ®Google Scholar
• Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer6(1), 38–51 (2006).
   PubMed Web of Science ®Google Scholar
• Rosato RR, Grant S. Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin. Ther. Targets9(4), 809–824 (2005).
   PubMed Web of Science ®Google Scholar
• Caron C, Boyault C, Khochbin S. Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability. Bioessays27(4), 408–415 (2005).
   PubMed Web of Science ®Google Scholar
• Butler LM, Zhou X, Xu WS et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc. Natl Acad. Sci. USA99(18), 11700–11705 (2002).
   PubMed Web of Science ®Google Scholar
• Marchion DC, Bicaku E, Daud AI et al. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J. Cell Biochem.92(2), 223–237 (2004).
   PubMed Web of Science ®Google Scholar
• Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res.65(9), 3815–3822 (2005).
   PubMed Web of Science ®Google Scholar
• Munster PN, Troso-Sandoval T, Rosen N et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res.61(23), 8492–8497 (2001).
   PubMed Web of Science ®Google Scholar
• Secrist JP, Zhou X, Richon VM. HDAC inhibitors for the treatment of cancer. Curr. Opin. Investig. Drugs4(12), 1422–1427 (2003).
   PubMedGoogle Scholar
• Gray SG, Qian CN, Furge K, Guo X, Teh BT. Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int. J. Oncol.24(4), 773–795 (2004).
   PubMed Web of Science ®Google Scholar
• Peart MJ, Smyth GK, van Laar RK et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA102(10), 3697–3702 (2005).
   PubMed Web of Science ®Google Scholar
• Della Ragione F, Criniti V, Della Pietra V et al. Genes modulated by histone acetylation as new effectors of butyrate activity. FEBS Lett.499(3), 199–204 (2001).
   PubMed Web of Science ®Google Scholar
• Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr.5(4–5), 245–253 (1996).
   PubMed Web of Science ®Google Scholar
• Marks PA, Richon VM, Miller T, Kelly WK. Histone deacetylase inhibitors. Adv. Cancer Res.91, 137–168 (2004).
   PubMed Web of Science ®Google Scholar
• Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl Acad. Sci. USA97(18), 10014–10019 (2000).
   PubMed Web of Science ®Google Scholar
• Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J. Clin. Oncol.23(17), 3971–3993 (2005).
   PubMed Web of Science ®Google Scholar
• Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl Acad. Sci. USA101(5), 1241–1246 (2004).
   PubMed Web of Science ®Google Scholar
• Sambucetti LC, Fischer DD, Zabludoff S et al. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol. Chem.274(49), 34940–34947 (1999).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Fatima N, Dufau ML. Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription. Mol. Cell. Biol.25(18), 7929–7939 (2005).
   PubMed Web of Science ®Google Scholar
• Reid G, Metivier R, Lin CY et al. Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor α, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene24(31), 4894–4907 (2005).
   PubMed Web of Science ®Google Scholar
• Archer SY, Meng S, Shei A, Hodin RA. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc. Natl Acad. Sci. USA95(12), 6791–6796 (1998).
   PubMed Web of Science ®Google Scholar
• Archer SY, Johnson J, Kim HJ et al. The histone deacetylase inhibitor butyrate downregulates cyclin B1 gene expression via a p21/WAF-1-dependent mechanism in human colon cancer cells. Am. J. Physiol. Gastrointest. Liver Physiol.289(4), G696–G703 (2005).
   PubMed Web of Science ®Google Scholar
• Hu J, Colburn NH. Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-κB/p65 DNA binding. Mol. Cancer Res.3(2), 100–109 (2005).
   PubMed Web of Science ®Google Scholar
• Kurz EU, Wilson SE, Leader KB et al. The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II α expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol. Cancer Ther.1(2), 121–131 (2002).
   Web of Science ®Google Scholar
• Li GC, Zhang X, Pan TJ, Chen Z, Ye ZQ. Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest. Int. J. Urol.13(5), 581–586 (2006).
   PubMed Web of Science ®Google Scholar
• Marks PA, Michaeli J, Jackson J, Richon VM, Rifkind RA. Induced differentiation of murine erythroleukemia cells (MELC) by polar compounds: marked increased sensitivity of vincristine resistant MELC. Prog. Clin. Biol. Res.316B, 171–181 (1989).
   PubMedGoogle Scholar
• Marks PA, Richon VM, Kiyokawa H, Rifkind RA. Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process. Proc. Natl Acad. Sci. USA91(22), 10251–10254 (1994).
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay NK, Weisberg E, Gilchrist D et al. Effectiveness of trichostatin A as a potential candidate for anticancer therapy in non-small-cell lung cancer. Ann. Thorac. Surg.81(3), 1034–1042 (2006).
   PubMed Web of Science ®Google Scholar
• Phillips A, Bullock T, Plant N. Sodium valproate induces apoptosis in the rat hepatoma cell line, FaO. Toxicology192(2–3), 219–227 (2003).
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Robey R, Sandor V et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood98(9), 2865–2868 (2001).
   PubMed Web of Science ®Google Scholar
• Planchon P, Magnien V, Beaupain R et al. Differential effects of butyrate derivatives on human breast cancer cells grown as organotypic nodules in vitro and as xenografts in vivo. In vivo6(6), 605–610 (1992).
   PubMedGoogle Scholar
• Rosato RR, Maggio SC, Almenara JA et al. The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Mol. Pharmacol.69(1), 216–225 (2006).
   PubMed Web of Science ®Google Scholar
• Ryu JK, Lee WJ, Lee KH et al. SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines. Cancer Lett.237(1), 143–154 (2006).
   PubMed Web of Science ®Google Scholar
• Takai N, Ueda T, Nishida M, Nasu K, Narahara H. Anticancer activity of MS-275, a novel histone deacetylase inhibitor, against human endometrial cancer cells. Anticancer Res.26(2A), 939–945 (2006).
   PubMed Web of Science ®Google Scholar
• Tsai SC, Valkov N, Yang WM et al. Histone deacetylase interacts directly with DNA topoisomerase II. Nat. Genet.26(3), 349–353 (2000).
   PubMed Web of Science ®Google Scholar
• Weisberg E, Catley L, Kujawa J et al. Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo. Leukemia18(12), 1951–1963 (2004).
   PubMed Web of Science ®Google Scholar
• Wetzel M, Premkumar DR, Arnold B, Pollack IF. Effect of trichostatin A, a histone deacetylase inhibitor, on glioma proliferation in vitro by inducing cell cycle arrest and apoptosis. J. Neurosurg.103(Suppl. 6), 549–556 (2005).
   PubMed Web of Science ®Google Scholar
• Vrana JA, Decker RH, Johnson CR et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene18(50), 7016–7025 (1999).
   PubMed Web of Science ®Google Scholar
• Sandor V, Senderowicz A, Mertins S et al. p21-dependent g(1) arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br. J. Cancer83(6), 817–825 (2000).
   PubMed Web of Science ®Google Scholar
• Abe M, Kufe DW. Sodium butyrate induction of milk-related antigens in human MCF-7 breast carcinoma cells. Cancer Res.44(10), 4574–4577 (1984).
   PubMed Web of Science ®Google Scholar
• Davis T, Kennedy C, Chiew YE, Clarke CL, deFazio A. Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clin. Cancer Res.6(11), 4334–4342 (2000).
   PubMed Web of Science ®Google Scholar
• Zhou Q, Melkoumian ZK, Lucktong A et al. Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1. J. Biol. Chem.275(45), 35256–35263 (2000).
   PubMed Web of Science ®Google Scholar
• Wang S, Yan-Neale Y, Cai R, Alimov I, Cohen D. Activation of mitochondrial pathway is crucial for tumor selective induction of apoptosis by LAQ824. Cell Cycle5(15), 1662–1668 (2006).
   PubMed Web of Science ®Google Scholar
• Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell4(1), 13–18 (2003).
   PubMed Web of Science ®Google Scholar
• Peart MJ, Tainton KM, Ruefli AA et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res.63(15), 4460–4471 (2003).
   PubMed Web of Science ®Google Scholar
• Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl Cancer Inst.92(15), 1210–1216 (2000).
   PubMed Web of Science ®Google Scholar
• Rosato RR, Almenara JA, Dai Y, Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther.2(12), 1273–1284 (2003).
   PubMed Web of Science ®Google Scholar
• Zhao Y, Tan J, Zhuang L et al. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc. Natl Acad. Sci. USA102(44), 16090–16095 (2005).
   PubMed Web of Science ®Google Scholar
• Rahmani M, Reese E, Dai Y et al. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Mol. Pharmacol.67(4), 1166–1176 (2005).
   PubMed Web of Science ®Google Scholar
• Sawa H, Murakami H, Ohshima Y et al. Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad. Brain Tumor Pathol.18(2), 109–114 (2001).
   PubMedGoogle Scholar
• Strait KA, Warnick CT, Ford CD et al. Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad. Mol. Cancer Ther.4(4), 603–611 (2005).
   PubMed Web of Science ®Google Scholar
• Bali P, Pranpat M, Swaby R et al. Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2. Clin. Cancer Res.11(17), 6382–6389 (2005).
   PubMed Web of Science ®Google Scholar
• Sutheesophon K, Kobayashi Y, Takatoku MA et al. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib. Acta Haematol.115(1–2), 78–90 (2006).
   PubMed Web of Science ®Google Scholar
• Cao XX, Mohuiddin I, Ece F, McConkey DJ, Smythe WR. Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am. J. Respir. Cell Mol. Biol.25(5), 562–568 (2001).
   PubMed Web of Science ®Google Scholar
• Shankar S, Singh TR, Fandy TE et al. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Int. J. Mol. Med.16(6), 1125–1138 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang XD, Gillespie SK, Borrow JM, Hersey P. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol. Cancer Ther.3(4), 425–435 (2004).
   PubMed Web of Science ®Google Scholar
• Muhlethaler-Mottet A, Flahaut M, Bourloud KB et al. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio. BMC Cancer6, 214 (2006).
   PubMed Web of Science ®Google Scholar
• Kim HR, Kim EJ, Yang SH et al. Trichostatin A induces apoptosis in lung cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway? Exp. Mol. Med.38(6), 616–624 (2006).
   PubMed Web of Science ®Google Scholar
• Insinga A, Monestiroli S, Ronzoni S et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med.11(1), 71–76 (2005).
   PubMed Web of Science ®Google Scholar
• Hirano T. The ABCs of SMC proteins: two-armed ATPases for chromosome condensation, cohesion, and repair. Genes Dev.16(4), 399–414 (2002).
   PubMed Web of Science ®Google Scholar
• Wei Y, Yu L, Bowen J, Gorovsky MA, Allis CD. Phosphorylation of histone H3 is required for proper chromosome condensation and segregation. Cell97(1), 99–109 (1999).
   PubMed Web of Science ®Google Scholar
• Hayakawa T, Haraguchi T, Masumoto H, Hiraoka Y. Cell cycle behavior of human HP1 subtypes: distinct molecular domains of HP1 are required for their centromeric localization during interphase and metaphase. J. Cell Sci.116(Pt 16), 3327–3338 (2003).
   PubMed Web of Science ®Google Scholar
• Noma K, Sugiyama T, Cam H et al. RITS acts in cis to promote RNA interference-mediated transcriptional and post-transcriptional silencing. Nat. Genet.36(11), 1174–1180 (2004).
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Dor Y, Herbert JM et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature394(6692), 485–490 (1998).
   PubMed Web of Science ®Google Scholar
• Nor JE, Christensen J, Mooney DJ, Polverini PJ. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am. J. Pathol.154(2), 375–384 (1999).
   PubMed Web of Science ®Google Scholar
• Kim MS, Kwon HJ, Lee YM et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med.7(4), 437–443 (2001).
   PubMed Web of Science ®Google Scholar
• Deroanne CF, Bonjean K, Servotte S et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene21(3), 427–436 (2002).
   PubMed Web of Science ®Google Scholar
• Rossig L, Li H, Fisslthaler B et al. Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ. Res.91(9), 837–844 (2002).
   PubMed Web of Science ®Google Scholar
• Kwon HJ, Kim MS, Kim MJ, Nakajima H, Kim KW. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int. J. Cancer97(3), 290–296 (2002).
   PubMed Web of Science ®Google Scholar
• Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res.61(4), 1477–1485 (2001).
   PubMed Web of Science ®Google Scholar
• Qian DZ, Kato Y, Shabbeer S et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin. Cancer Res.12(2), 634–642 (2006).
   PubMed Web of Science ®Google Scholar
• Qian DZ, Wang X, Kachhap SK et al. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res.64(18), 6626–6634 (2004).
   PubMed Web of Science ®Google Scholar
• Huang N, Katz JP, Martin DR, Wu GD. Inhibition of IL-8 gene expression in Caco-2 cells by compounds which induce histone hyperacetylation. Cytokine9(1), 27–36 (1997).
   PubMed Web of Science ®Google Scholar
• Koyama Y, Adachi M, Sekiya M, Takekawa M, Imai K. Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis. Blood96(4), 1490–1495 (2000).
   PubMed Web of Science ®Google Scholar
• Takahashi I, Miyaji H, Yoshida T, Sato S, Mizukami T. Selective inhibition of IL-2 gene expression by trichostatin A, a potent inhibitor of mammalian histone deacetylase. J. Antibiot. (Tokyo)49(5), 453–457 (1996).
   PubMed Web of Science ®Google Scholar
• Blanchard F, Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov. Today10(3), 197–204 (2005).
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Inhibitors of histone deacetylases as anti-inflammatory drugs. Ernst Schering Res. Found. Workshop56, 45–60 (2006).
   Google Scholar
• Camelo S, Iglesias AH, Hwang D et al. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J. Neuroimmunol.164(1–2), 10–21 (2005).
   PubMed Web of Science ®Google Scholar
• Chung YL, Lee MY, Wang AJ, Yao LF. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol. Ther.8(5), 707–717 (2003).
   PubMed Web of Science ®Google Scholar
• Reddy P, Maeda Y, Hotary K et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc. Natl Acad. Sci. USA101(11), 3921–3926 (2004).
   PubMed Web of Science ®Google Scholar
• Brogdon J, Xu Y, Szabo S et al. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood109(3), 1123–1130 (2007).
   PubMed Web of Science ®Google Scholar
• Leoni F, Zaliani A, Bertolini G et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc. Natl Acad. Sci. USA99(5), 2995–3000 (2002).
   PubMed Web of Science ®Google Scholar
• Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J. Clin. Invest.111(4), 539–552 (2003).
   PubMed Web of Science ®Google Scholar
• Suuronen T, Huuskonen J, Pihlaja R, Kyrylenko S, Salminen A. Regulation of microglial inflammatory response by histone deacetylase inhibitors. J. Neurochem.87(2), 407–416 (2003).
   PubMed Web of Science ®Google Scholar
• Ito K, Lim S, Caramori G et al. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc. Natl Acad. Sci. USA99(13), 8921–8926 (2002).
   PubMed Web of Science ®Google Scholar
• Blanchard F, Kinzie E, Wang Y et al. FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins. Oncogene21(41), 6264–6277 (2002).
   PubMed Web of Science ®Google Scholar
• Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J.19(6), 1176–1179 (2000).
   PubMed Web of Science ®Google Scholar
• Polevoda B, Sherman F. The diversity of acetylated proteins. Genome Biol.3(5), reviews0006 (2002).
   PubMedGoogle Scholar
• Wang R, Cherukuri P, Luo J. Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J. Biol. Chem.280(12), 11528–11534 (2005).
   PubMed Web of Science ®Google Scholar
• Yuan ZL, Guan YJ, Chatterjee D, Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science307(5707), 269–273 (2005).
   PubMed Web of Science ®Google Scholar
• Martinez-Balbas MA, Bauer UM, Nielsen SJ, Brehm A, Kouzarides T. Regulation of E2F1 activity by acetylation. EMBO J.19(4), 662–671 (2000).
   PubMed Web of Science ®Google Scholar
• Marzio G, Wagener C, Gutierrez MI et al. E2F family members are differentially regulated by reversible acetylation. J. Biol. Chem.275(15), 10887–10892 (2000).
   PubMed Web of Science ®Google Scholar
• Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell90(4), 595–606 (1997).
   PubMed Web of Science ®Google Scholar
• Sykes SM, Mellert HS, Holbert MA et al. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol. Cell24(6), 841–851 (2006).
   PubMed Web of Science ®Google Scholar
• Kramer OH, Baus D, Knauer SK et al. Acetylation of Stat1 modulates NF-κB activity. Genes Dev.20(4), 473–485 (2006).
   PubMed Web of Science ®Google Scholar
• Nusinzon I, Horvath CM. Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc. Natl Acad. Sci. USA100(25), 14742–14747 (2003).
   PubMed Web of Science ®Google Scholar
• Vries RG, Prudenziati M, Zwartjes C et al. A specific lysine in c-Jun is required for transcriptional repression by E1A and is acetylated by p300. EMBO J.20(21), 6095–6103 (2001).
   PubMed Web of Science ®Google Scholar
• Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene363, 15–23 (2005).
   PubMed Web of Science ®Google Scholar
• Piacentini P, Donadelli M, Costanzo C et al. Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch.448(6), 797–804 (2006).
   PubMed Web of Science ®Google Scholar
• Sato T, Suzuki M, Sato Y, Echigo S, Rikiishi H. Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells. Int. J. Oncol.28(5), 1233–1241 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang X, Yashiro M, Ren J, Hirakawa K. Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. Oncol. Rep.16(3), 563–568 (2006).
   PubMed Web of Science ®Google Scholar
• Chobanian NH, Greenberg VL, Gass JM et al. Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status. Anticancer Res.24(2B), 539–545 (2004).
   PubMed Web of Science ®Google Scholar
• Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol. Cancer Ther.4(12), 1993–2000 (2005).
   PubMed Web of Science ®Google Scholar
• Kim MS, Blake M, Baek JH et al. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res.63(21), 7291–7300 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson CA, Padget K, Austin CA, Turner BM. Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis. J. Biol. Chem.276(7), 4539–4542 (2001).
   PubMed Web of Science ®Google Scholar
• Bevins RL, Zimmer SG. It’s about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells. Cancer Res.65(15), 6957–6966 (2005).
   PubMed Web of Science ®Google Scholar
• Acharya MR, Figg WD. Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue. Cancer Biol. Ther.3(8), 719–720 (2004).
   PubMed Web of Science ®Google Scholar
• Maggio SC, Rosato RR, Kramer LB et al. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res.64(7), 2590–2600 (2004).
   PubMed Web of Science ®Google Scholar
• Adachi M, Zhang Y, Zhao X et al. Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells. Clin. Cancer Res.10(11), 3853–3862 (2004).
   PubMed Web of Science ®Google Scholar
• Bai J, Demirjian A, Sui J, Marasco W, Callery MP. Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. Biochem. Biophys. Res. Commun.348(4), 1245–1253 (2006).
   PubMed Web of Science ®Google Scholar
• Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin. Cancer Res.10(11), 3839–3852 (2004).
   PubMed Web of Science ®Google Scholar
• Yu C, Rahmani M, Conrad D et al. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood102(10), 3765–3774 (2003).
   PubMed Web of Science ®Google Scholar
• Coffey DC, Kutko MC, Glick RD et al. Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Med. Pediatr. Oncol.35(6), 577–581 (2000).
   PubMedGoogle Scholar
• Kuendgen A, Schmid M, Schlenk R et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer106(1), 112–119 (2006).
   PubMed Web of Science ®Google Scholar
• Kuendgen A, Strupp C, Aivado M et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood104(5), 1266–1269 (2004).
   PubMed Web of Science ®Google Scholar
• Bug G, Ritter M, Wassmann B et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer104(12), 2717–2725 (2005).
   PubMed Web of Science ®Google Scholar
• Massart C, Denais A, Gibassier J. Effect of all-trans retinoic acid and sodium butyrate in vitro and in vivo on thyroid carcinoma xenografts. Anticancer Drugs17(5), 559–563 (2006).
   PubMed Web of Science ®Google Scholar
• Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet.21(1), 103–107 (1999).
   PubMed Web of Science ®Google Scholar
• Gore SD, Baylin S, Sugar E et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res.66(12), 6361–6369 (2006).
   PubMed Web of Science ®Google Scholar
• Hurtubise A, Momparler RL. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-aza-2´-deoxycytidine (decitabine) on human breast carcinoma cells. Cancer Chemother. Pharmacol.58(5), 618–625 (2006).
   PubMed Web of Science ®Google Scholar
• Zhu WG, Lakshmanan RR, Beal MD, Otterson GA. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res.61(4), 1327–1333 (2001).
   PubMed Web of Science ®Google Scholar
• Camphausen K, Burgan W, Cerra M et al. Enhanced radiation-induced cell killing and prolongation of γH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res.64(1), 316–321 (2004).
   PubMed Web of Science ®Google Scholar
• Flatmark K, Nome RV, Folkvord S et al. Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition. Radiat. Oncol.1(1), 25 (2006).
   PubMedGoogle Scholar
• Kim MS, Baek JH, Chakravarty D, Sidransky D, Carrier F. Sensitization to UV-induced apoptosis by the histone deacetylase inhibitor trichostatin A (TSA). Exp. Cell Res.306(1), 94–102 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Adachi M, Kawamura R et al. Bmf contributes to histone deacetylase inhibitor-mediated enhancing effects on apoptosis after ionizing radiation. Apoptosis11(8), 1349–1357 (2006).
   PubMed Web of Science ®Google Scholar
• Chen Z, Brand NJ, Chen A et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-α locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J.12(3), 1161–1167 (1993).
   PubMed Web of Science ®Google Scholar
• de The H, Lavau C, Marchio A et al. The PML-RAR α fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell66(4), 675–684 (1991).
   PubMed Web of Science ®Google Scholar
• Grignani F, De Matteis S, Nervi C et al. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature391(6669), 815–818 (1998).
   PubMed Web of Science ®Google Scholar
• Ruthardt M, Testa U, Nervi C et al. Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor α (RAR α) and PLZF-RAR α fusion proteins on retinoic acid signalling. Mol. Cell. Biol.17(8), 4859–4869 (1997).
   PubMed Web of Science ®Google Scholar
• Senyuk V, Chakraborty S, Mikhail FM et al. The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells. Oncogene21(20), 3232–3240 (2002).
   PubMed Web of Science ®Google Scholar
• Minucci S, Horn V, Bhattacharyya N et al. A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells. Proc. Natl Acad. Sci. USA94(21), 11295–11300 (1997).
   PubMed Web of Science ®Google Scholar
• He LZ, Guidez F, Tribioli C et al. Distinct interactions of PML–RARα and PLZF–RARα with co-repressors determine differential responses to RA in APL. Nat. Genet.18(2), 126–135 (1998).
   PubMed Web of Science ®Google Scholar
• Lin RJ, Nagy L, Inoue S et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature391(6669), 811–814 (1998).
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Ni X et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood109(1), 31–39 (2007).
   PubMed Web of Science ®Google Scholar
• Kelly WK, Richon VM, O’Connor O et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res.9(10 Pt 1), 3578–3588 (2003).
   PubMed Web of Science ®Google Scholar
• Cohen LA, Amin S, Marks PA et al. Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res.19(6B), 4999–5005 (1999).
   PubMed Web of Science ®Google Scholar
• Kelly WK, O’Connor OA, Krug LM et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol.23(17), 3923–3931 (2005).
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Heaney ML, Schwartz L et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol.24(1), 166–173 (2006).
   PubMed Web of Science ®Google Scholar
• Sandor V, Bakke S, Robey RW et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res.8(3), 718–728 (2002).
   PubMed Web of Science ®Google Scholar
• Marshall JL, Rizvi N, Kauh J et al. A Phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J. Exp. Ther. Oncol.2(6), 325–332 (2002).
   PubMedGoogle Scholar
• Piekarz RL, Frye AR, Wright JJ et al. Cardiac studies in patients treated with depsipeptide, FK228, in a Phase II trial for T-cell lymphoma. Clin. Cancer Res.12(12), 3762–3773 (2006).
   PubMed Web of Science ®Google Scholar
• Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA. A Phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin. Genitourin. Cancer5(1), 57–60 (2006).
   PubMed Web of Science ®Google Scholar
• Shah MH, Binkley P, Chan K et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin. Cancer Res.12(13), 3997–4003 (2006).
   PubMed Web of Science ®Google Scholar
• Fouladi M, Furman WL, Chin T et al. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children’s Oncology Group report. J. Clin. Oncol.24(22), 3678–3685 (2006).
   PubMed Web of Science ®Google Scholar
• Gottlicher M. Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann. Hematol.83(Suppl. 1), S91–S92 (2004).
   PubMedGoogle Scholar
• Gottlicher M, Minucci S, Zhu P et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J.20(24), 6969–6978 (2001).
   PubMed Web of Science ®Google Scholar
• Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res.64(3), 1079–1086 (2004).
   PubMed Web of Science ®Google Scholar
• Williams RS, Cheng L, Mudge AW, Harwood AJ. A common mechanism of action for three mood-stabilizing drugs. Nature417(6886), 292–295 (2002).
   PubMed Web of Science ®Google Scholar
• Phiel CJ, Zhang F, Huang EY et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem.276(39), 36734–36741 (2001).
   PubMed Web of Science ®Google Scholar
• Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G. Antileukemia activity of the combination of 5-aza-2´-deoxycytidine with valproic acid. Leuk. Res.29(7), 739–748 (2005).
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B et al. Phase I/II study of the combination of 5-aza-2´-deoxycytidine with valproic acid in patients with leukemia. Blood108(10), 3271–3279 (2006).
   PubMed Web of Science ®Google Scholar
• Atadja P, Hsu M, Kwon P et al. Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824. Novartis Found. Symp.259, 249–266; discussion 266–268, 285–288 (2004).
   PubMedGoogle Scholar
• Bali P, Pranpat M, Bradner J et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem.280(29), 26729–26734 (2005).
   PubMed Web of Science ®Google Scholar
• Giles F, Fischer T, Cortes J et al. A Phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin. Cancer Res.12(15), 4628–4635 (2006).
   PubMed Web of Science ®Google Scholar
• Ryan QC, Headlee D, Acharya M et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J. Clin. Oncol.23(17), 3912–3922 (2005).
   PubMed Web of Science ®Google Scholar
• Gilbert J, Baker SD, Bowling MK et al. A Phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin. Cancer Res.7(8), 2292–2300 (2001).
   PubMed Web of Science ®Google Scholar
• Plumb JA, Finn PW, Williams RJ et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol. Cancer Ther.2(8), 721–728 (2003).
   PubMed Web of Science ®Google Scholar
• Qian X, LaRochelle WJ, Ara G et al. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol. Cancer Ther.5(8), 2086–2095 (2006).
   PubMed Web of Science ®Google Scholar
• Munster PN, Marchion DC, Bicaku E et al. Phase I trial of histone deacetylase inhibition by valproic acid (VPA) followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J. Clin. Oncol. (2007) (In Press).
   PubMedGoogle Scholar
• Laherty CD, Yang WM, Sun JM et al. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell89(3), 349–356 (1997).
   PubMed Web of Science ®Google Scholar
• Hassig CA, Fleischer TC, Billin AN, Schreiber SL, Ayer DE. Histone deacetylase activity is required for full transcriptional repression by mSin3A. Cell89(3), 341–347 (1997).
   PubMed Web of Science ®Google Scholar
• Nagy L, Kao HY, Chakravarti D et al. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell89(3), 373–380 (1997).
   PubMed Web of Science ®Google Scholar
• Humphrey GW, Wang Y, Russanova VR et al. Stable histone deacetylase complexes distinguished by the presence of SANT domain proteins CoREST/kiaa0071 and Mta-L1. J. Biol. Chem.276(9), 6817–6824 (2001).
   PubMed Web of Science ®Google Scholar
• You A, Tong JK, Grozinger CM, Schreiber SL. CoREST is an integral component of the CoREST–human histone deacetylase complex. Proc. Natl Acad. Sci. USA98(4), 1454–1458 (2001).
   PubMed Web of Science ®Google Scholar
• Glaser KB, Li J, Staver MJ et al. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem. Biophys. Res. Commun.310(2), 529–536 (2003).
   PubMed Web of Science ®Google Scholar
• Lehrmann H, Pritchard LL, Harel-Bellan A. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv. Cancer Res.86, 41–65 (2002).
   PubMed Web of Science ®Google Scholar
• Calonghi N, Cappadone C, Pagnotta E et al. Histone deacetylase 1: a target of 9-hydroxystearic acid in the inhibition of cell growth in human colon cancer. J. Lipid Res.46(8), 1596–1603 (2005).
   PubMed Web of Science ®Google Scholar
• Lagger G, O’Carroll D, Rembold M et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J.21(11), 2672–2681 (2002).
   PubMed Web of Science ®Google Scholar
• Stadler JA, Shkumatava A, Norton WH et al. Histone deacetylase 1 is required for cell cycle exit and differentiation in the zebrafish retina. Dev. Dyn.233(3), 883–889 (2005).
   PubMed Web of Science ®Google Scholar
• Huang BH, Laban M, Leung CH et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ.12(4), 395–404 (2005).
   PubMed Web of Science ®Google Scholar
• Hrzenjak A, Moinfar F, Kremser ML et al. Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol. Cancer Ther.5(9), 2203–2210 (2006).
   PubMed Web of Science ®Google Scholar
• Wilson AJ, Byun DS, Popova N et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J. Biol. Chem.281(19), 13548–13558 (2006).
   PubMed Web of Science ®Google Scholar
• Fischle W, Dequiedt F, Fillion M et al. Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J. Biol. Chem.276(38), 35826–35835 (2001).
   PubMed Web of Science ®Google Scholar
• Fischle W, Dequiedt F, Hendzel MJ et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell9(1), 45–57 (2002).
   PubMed Web of Science ®Google Scholar
• Hug BA. HDAC4: a corepressor controlling bone development. Cell119(4), 448–449 (2004).
   PubMed Web of Science ®Google Scholar
• Dressel U, Bailey PJ, Wang SC et al. A dynamic role for HDAC7 in MEF2-mediated muscle differentiation. J. Biol. Chem.276(20), 17007–17013 (2001).
   PubMed Web of Science ®Google Scholar
• McKinsey TA, Zhang CL, Lu J, Olson EN. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature408(6808), 106–111 (2000).
   PubMed Web of Science ®Google Scholar
• Miska EA, Langley E, Wolf D et al. Differential localization of HDAC4 orchestrates muscle differentiation. Nucleic Acids Res.29(16), 3439–3447 (2001).
   PubMed Web of Science ®Google Scholar
• Hubbert C, Guardiola A, Shao R et al. HDAC6 is a microtubule-associated deacetylase. Nature417(6887), 455–458 (2002).
   PubMed Web of Science ®Google Scholar
• Kovacs JJ, Hubbert C, Yao TP. The HDAC complex and cytoskeleton. Novartis Found. Symp.259, 170–177; discussion 178–181, 223–225 (2004).
   PubMedGoogle Scholar
• Matsuyama A, Shimazu T, Sumida Y et al. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J.21(24), 6820–6831 (2002).
   PubMed Web of Science ®Google Scholar
• Chang S, Young BD, Li S et al. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell126(2), 321–334 (2006).
   PubMed Web of Science ®Google Scholar
• Waltregny D, De Leval L, Glenisson W et al. Expression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues. Am. J. Pathol.165(2), 553–564 (2004).
   PubMed Web of Science ®Google Scholar
• Waltregny D, Glenisson W, Tran SL et al. Histone deacetylase HDAC8 associates with smooth muscle α-actin and is essential for smooth muscle cell contractility. FASEB J.19(8), 966–968 (2005).
   PubMed Web of Science ®Google Scholar
• Kramer OH, Zhu P, Ostendorff HP et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J.22(13), 3411–3420 (2003).
   PubMed Web of Science ®Google Scholar
• Hu E, Dul E, Sung CM et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Ther.307(2), 720–728 (2003).
   PubMed Web of Science ®Google Scholar
• Ropero S, Fraga MF, Ballestar E et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat. Genet.38(5), 566–569 (2006).
   PubMed Web of Science ®Google Scholar